Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
XenoPort, Inc.
ClinicalTrials.gov Identifier:
NCT00643760
First received: February 19, 2008
Last updated: July 15, 2013
Last verified: January 2013
Results First Received: April 21, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Neuropathy, Diabetic
Interventions: Drug: Placebo
Drug: GEn 1200mg/day
Drug: GEn 2400mg/day
Drug: GEn 3600mg/day
Drug: Pregabalin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Placebo Three 600 milligram (mg) gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn, placebo tablets taken orally twice daily (morning and evening); one 100 mg pregabalin (PGB) placebo capsule taken orally three times daily (morning, midday, and evening).
GEn 1200 mg/Day One 600 mg extended release (ER) GEn tablet and two 600 mg GEn placebo tablets taken orally twice daily (morning and evening); one 100 mg PGB placebo capsule taken orally three times daily (morning, midday, and evening).
GEn 2400 mg/Day Two 600 mg ER GEn tablets and one 600 mg GEn placebo tablet taken orally twice daily (morning and evening); one 100 mg PGB placebo capsule taken orally three times daily (morning, midday, and evening).
GEn 3600 mg/Day Three 600 mg ER GEn tablets taken orally twice daily (morning and evening); one 100 mg PGB placebo capsule taken orally three times daily (morning, midday, and evening).
PGB 300 mg/Day Three 600 mg GEn placebo tablets taken orally twice daily (morning and evening); one 100 mg PGB capsule taken orally three times daily (morning, midday, and evening).

Participant Flow:   Overall Study
    Placebo     GEn 1200 mg/Day     GEn 2400 mg/Day     GEn 3600 mg/Day     PGB 300 mg/Day  
STARTED     120     62     56     117     66  
Safety Population/Treated With Drug     120     62     56     116     66  
ITT Population     120     62     56     116     66  
COMPLETED     90     47     37     79     47  
NOT COMPLETED     30     15     19     38     19  
Adverse Event                 11                 5                 12                 21                 6  
Lack of Efficacy                 3                 1                 0                 4                 3  
Protocol Violation                 7                 6                 4                 4                 6  
Lost to Follow-up                 6                 2                 1                 3                 3  
Investigator Discretion                 0                 0                 0                 2                 0  
Withdrawal by Subject                 3                 1                 2                 4                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo Three 600 milligram (mg) gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn, placebo tablets taken orally twice daily (morning and evening); one 100 mg pregabalin (PGB) placebo capsule taken orally three times daily (morning, midday, and evening).
GEn 1200 mg/Day One 600 mg extended release (ER) GEn tablet and two 600 mg GEn placebo tablets taken orally twice daily (morning and evening); one 100 mg PGB placebo capsule taken orally three times daily (morning, midday, and evening).
GEn 2400 mg/Day Two 600 mg ER GEn tablets and one 600 mg GEn placebo tablet taken orally twice daily (morning and evening); one 100 mg PGB placebo capsule taken orally three times daily (morning, midday, and evening).
GEn 3600 mg/Day Three 600 mg ER GEn tablets taken orally twice daily (morning and evening); one 100 mg PGB placebo capsule taken orally three times daily (morning, midday, and evening).
PGB 300 mg/Day Three 600 mg GEn placebo tablets taken orally twice daily (morning and evening); one 100 mg PGB capsule taken orally three times daily (morning, midday, and evening).
Total Total of all reporting groups

Baseline Measures
    Placebo     GEn 1200 mg/Day     GEn 2400 mg/Day     GEn 3600 mg/Day     PGB 300 mg/Day     Total  
Number of Participants  
[units: participants]
  120     62     56     116     66     420  
Age [1]
[units: Years]
Mean ± Standard Deviation
  60.1  ± 10.63     57.5  ± 10.32     60.8  ± 8.97     57.5  ± 9.87     57.7  ± 10.59     58.7  ± 10.20  
Gender [2]
[units: Participants]
           
Female     47     28     19     45     32     171  
Male     73     34     37     71     34     249  
Race/Ethnicity, Customized [3]
[units: participants]
           
African American/African Heritage     20     15     7     20     12     74  
American Indian or Alaskan Native     2     0     0     0     0     2  
Asian - Central/South Asian Heritage     0     0     0     1     0     1  
Asian - South East Asian Heritage     0     1     0     2     0     3  
White - Arabic/North African Heritage     0     2     2     1     0     5  
White - White/Caucasian/European Heritage     98     44     45     89     52     328  
Mixed Race     0     0     1     1     0     2  
Not Provided     0     0     1     2     2     5  
[1] Age in years of the Intent-to-Treat (ITT) Population, comprised of all randomized participants who took at least one dose of investigational product and provided at least one post-baseline efficacy measurement, was used for all baseline characteristics. This population does not include all participants randomized to study treatment.
[2] Gender of the ITT Population, comprised of all randomized participants who took at least one dose of investigational product and provided at least one post-baseline efficacy measurement, was used for all baseline characteristics. This population does not include all participants randomized to study treatment.
[3] Race of the ITT Population, comprised of all randomized participants who took at least one dose of investigational product and provided at least one post-baseline efficacy measurement, was used for all baseline characteristics. This population does not include all participants randomized to study treatment.



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change From Baseline in the Mean 24-hour Average Pain Intensity (API) Score at End of Maintenance Treatment (EOMT) Using Last Observation Carried Forward (LOCF) Data   [ Time Frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit) ]

2.  Secondary:   Change From Baseline in the Mean Day-time Average Pain Intensity (API) Score at EOMT Using LOCF Data   [ Time Frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit) ]

3.  Secondary:   Change From Baseline in the Mean Night-time Average Pain Intensity (API) Score at EOMT Using LOCF Data   [ Time Frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit) ]

4.  Secondary:   Change From Baseline in the Mean Current (Morning) Pain Intensity Score at EOMT Using LOCF Data   [ Time Frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit) ]

5.  Secondary:   Change From Baseline in the Mean Current (Evening) Pain Intensity Score at EOMT Using LOCF Data   [ Time Frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit) ]

6.  Secondary:   Change From Baseline in the Mean Day-time Worst Pain Intensity Score at EOMT Using LOCF Data   [ Time Frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit) ]

7.  Secondary:   Change From Baseline in the Mean Night-time Worst Pain Intensity Score at EOMT Using LOCF Data   [ Time Frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit) ]

8.  Secondary:   Change From Baseline in the Mean Sleep Interference Score at EOMT Using LOCF Data   [ Time Frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit) ]

9.  Secondary:   Change From Baseline in the Mean Daily Dose of Rescue Medication at EOMT Using LOCF Data   [ Time Frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit) ]

10.  Secondary:   Change From Baseline in Pain Quality as Assessed by the Neuropathic Pain Scale (NPS) Summary Scores at EOMT Using LOCF Data   [ Time Frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit) ]

11.  Secondary:   Change From Baseline in Pain Characteristics and Intensity as Assessed by the Short Form-McGill Pain Questionnaire (SF-MPQ) at EOMT Using LOCF Data   [ Time Frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit) ]

12.  Secondary:   Change From Baseline in Pain Score After Taking a 50-foot Walk at EOMT   [ Time Frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit) ]

13.  Secondary:   Number of Participants Who Are Responders on the Patient Global Impression of Change (PGIC) Questionnaire at EOMT Using LOCF Data   [ Time Frame: EOMT (representing the earliest date of Week 13 visit/withdrawal visit) ]

14.  Secondary:   Number of Participants Who Are Responders on the Clinician Global Impression of Change (CGIC) Questionnaire at EOMT Using LOCF Data   [ Time Frame: EOMT (representing the earliest date of Week 13 visit/withdrawal visit) ]

15.  Secondary:   Number of Participants Achieving Various Levels of Percent Reduction From Baseline in the Mean 24-hour Average Pain Intensity Score at EOMT Using LOCF Data   [ Time Frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit) ]

16.  Secondary:   Time to Onset of Sustained Improvement in the 24-hour Average Pain Intensity Score   [ Time Frame: Any time post-baseline until date of last dose of study medication (up to Week 13) ]

17.  Secondary:   Change From Baseline in Severity of Pain and the Impact of Pain as Assessed by the Brief Pain Inventory (BPI) at EOMT Using LOCF Data   [ Time Frame: Baseline and EOMT ]

18.  Secondary:   Change From Baseline in Quality of Life as Assessed by the 36-Item Short Form Health Survey (SF-36) at EOMT Using LOCF Data   [ Time Frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit) ]

19.  Secondary:   Change From Baseline in Emotional Functioning as Assessed by the Profile of Mood States-Brief Form (POMS-B) at EOMT Using LOCF Data   [ Time Frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit) ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: XenoPort Call Center
Organization: XenoPort, Inc.
phone: 877-936-6778


No publications provided


Responsible Party: XenoPort, Inc.
ClinicalTrials.gov Identifier: NCT00643760     History of Changes
Other Study ID Numbers: 110448
Study First Received: February 19, 2008
Results First Received: April 21, 2011
Last Updated: July 15, 2013
Health Authority: United States: Food and Drug Administration